Acer Therapeutics has been granted a patent for crystalline forms of emetine dihydrochloride, including a specific formula. The patent covers manufacturing processes and methods of using these crystalline forms. GlobalData’s report on Acer Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Acer Therapeutics, Cancer immunotherapy was a key innovation area identified from patents.
Crystalline form of emetine dihydrochloride
A recently granted patent (Publication Number: US11884663B2) discloses a crystalline form of Compound I dihydrochloride, characterized by specific X-ray powder diffractograms. The patent claims various forms of the crystalline compound, each with distinct peaks in their diffractograms, such as Form 2, Form 4, Form 5, and Form 6. Additionally, the patent covers pharmaceutical compositions containing the crystalline form of Compound I dihydrochloride along with a pharmaceutically acceptable carrier, and optionally, other therapeutic agents like antiparasitic agents, antibiotics, antiviral agents, and agents for controlling a cytokine storm.
Furthermore, the patent describes methods of treating viral infections, including Flavivirus infections like Zika virus, West Nile virus, and dengue virus, as well as infections caused by Ebola virus, human immunodeficiency virus 1 (HIV-1), and various coronaviruses, including SARS-COV-2. The methods involve administering the crystalline form of Compound I dihydrochloride to the subject, with specific mention of treating COVID-19 in subjects not requiring hospitalization. The patent also highlights the potential use of the crystalline compound in managing diseases caused by SARS-COV-2, specifically mentioning COVID-19 and the absence of severe symptoms of Cytokine Release Syndrome in treated subjects.
To know more about GlobalData’s detailed insights on Acer Therapeutics, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
